JP2022532557A5 - - Google Patents

Info

Publication number
JP2022532557A5
JP2022532557A5 JP2021566150A JP2021566150A JP2022532557A5 JP 2022532557 A5 JP2022532557 A5 JP 2022532557A5 JP 2021566150 A JP2021566150 A JP 2021566150A JP 2021566150 A JP2021566150 A JP 2021566150A JP 2022532557 A5 JP2022532557 A5 JP 2022532557A5
Authority
JP
Japan
Application number
JP2021566150A
Other languages
Japanese (ja)
Other versions
JPWO2020227483A5 (https=
JP7723887B2 (ja
JP2022532557A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/031796 external-priority patent/WO2020227483A1/en
Publication of JP2022532557A publication Critical patent/JP2022532557A/ja
Publication of JP2022532557A5 publication Critical patent/JP2022532557A5/ja
Publication of JPWO2020227483A5 publication Critical patent/JPWO2020227483A5/ja
Priority to JP2025031484A priority Critical patent/JP2025078698A/ja
Application granted granted Critical
Publication of JP7723887B2 publication Critical patent/JP7723887B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021566150A 2019-05-08 2020-05-07 操作されたt細胞 Active JP7723887B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025031484A JP2025078698A (ja) 2019-05-08 2025-02-28 操作されたt細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962845311P 2019-05-08 2019-05-08
US62/845,311 2019-05-08
PCT/US2020/031796 WO2020227483A1 (en) 2019-05-08 2020-05-07 Engineered t cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025031484A Division JP2025078698A (ja) 2019-05-08 2025-02-28 操作されたt細胞

Publications (4)

Publication Number Publication Date
JP2022532557A JP2022532557A (ja) 2022-07-15
JP2022532557A5 true JP2022532557A5 (https=) 2023-05-15
JPWO2020227483A5 JPWO2020227483A5 (https=) 2023-05-15
JP7723887B2 JP7723887B2 (ja) 2025-08-15

Family

ID=73051184

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021566150A Active JP7723887B2 (ja) 2019-05-08 2020-05-07 操作されたt細胞
JP2025031484A Pending JP2025078698A (ja) 2019-05-08 2025-02-28 操作されたt細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025031484A Pending JP2025078698A (ja) 2019-05-08 2025-02-28 操作されたt細胞

Country Status (16)

Country Link
US (1) US12590136B2 (https=)
EP (1) EP3966235A4 (https=)
JP (2) JP7723887B2 (https=)
KR (1) KR20220030933A (https=)
CN (2) CN120939220A (https=)
AU (1) AU2020267641B2 (https=)
BR (1) BR112021022303A2 (https=)
CA (1) CA3139011A1 (https=)
CL (1) CL2021002935A1 (https=)
CO (1) CO2021016480A2 (https=)
EA (1) EA202193074A1 (https=)
IL (1) IL287777A (https=)
MA (1) MA55911A (https=)
MX (1) MX2021013588A (https=)
SG (1) SG11202111973RA (https=)
WO (1) WO2020227483A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
IL266628B2 (en) 2016-11-17 2024-06-01 Bluebird Bio Inc TGFBeta signal converter
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP3714941A1 (en) 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
KR20220030933A (ko) 2019-05-08 2022-03-11 메디진 이뮤노테라피스 게엠바하 조작된 t 세포
AU2021244594A1 (en) * 2020-03-27 2022-12-01 Regeneron Pharmaceuticals, Inc. T cell receptors
JP2024514556A (ja) * 2021-04-15 2024-04-02 レジェンド バイオテック ユーエスエイ インコーポレイテッド 融合タンパク質及びその使用法
TW202317602A (zh) * 2021-07-15 2023-05-01 福瑞德哈金森腫瘤中心 嵌合多肽
IL312182A (en) * 2021-10-20 2024-06-01 Fate Therapeutics Inc Effector cells and their use for autologous cell-based therapy against tumors
GB202115329D0 (en) * 2021-10-25 2021-12-08 Autolus Ltd Chimeric cytokine receptor
EP4479068A4 (en) * 2022-02-18 2026-01-07 Univ California ENHANCED MULTIPLICATION AND FUNCTION OF PRIMARY HUMAN NK CELLS BY A CHIMERICAL CYTOKINE RECEPTOR
USD1083734S1 (en) * 2022-08-01 2025-07-15 Hyundai Motor Company Wheel for automobile
JP2026503660A (ja) * 2023-01-27 2026-01-29 ジェンティバイオ インコーポレイテッド 操作された修復調節性t細胞
WO2025047925A1 (ja) * 2023-08-31 2025-03-06 国立大学法人三重大学 ハイブリッドt細胞受容体

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US7157091B1 (en) 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
AU2002321581C1 (en) 2001-08-31 2008-09-18 Adaptimmune Limited Soluble T cell receptor
US7311914B2 (en) 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
EP1783228A1 (en) 2005-11-08 2007-05-09 ETH Zürich Recombinant expression of multiprotein complexes using polygenes
WO2008053573A1 (fr) 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remède pour néoplasme malin
WO2011024791A1 (ja) 2009-08-25 2011-03-03 タカラバイオ株式会社 レチノイン酸存在下でのt細胞集団の製造方法
SG10201505217WA (en) 2010-07-09 2015-08-28 Biogen Hemophilia Inc Chimeric clotting factors
CN107164330A (zh) 2011-04-08 2017-09-15 贝勒医学院 使用嵌合细胞因子受体逆转肿瘤微环境的影响
DK2806883T3 (da) 2012-01-25 2019-07-22 Dnatrix Inc Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation
IL286786B (en) 2012-09-14 2022-09-01 The Us Secretary Department Of Health And Human Services Office Of Technology Transfer National Inst T cell receptors that recognize mhc mage–a3 are restricted type ii
GB2508414A (en) 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
CA2909701C (en) 2013-04-17 2022-12-06 Baylor College Of Medicine Immunosuppressive tgf-.beta. signal converter
WO2015017214A1 (en) 2013-07-29 2015-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
EP2944652A1 (en) 2014-05-13 2015-11-18 Technische Universität München Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
US10828353B2 (en) 2015-01-31 2020-11-10 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
US10227392B2 (en) 2015-04-06 2019-03-12 Acceleron Pharma Inc. ALK7:ActRIIB heteromultimers and uses thereof
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
CA2938473A1 (en) 2015-08-04 2017-02-04 Fiberbuilt Manufacturing Inc. Golf practice device
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
GB201604492D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SMT202100564T1 (it) 2016-04-08 2022-01-10 Adaptimmune Ltd Recettori di cellule t
PL3440105T3 (pl) 2016-04-08 2022-08-29 Immunocore Limited Receptory komórek t
RU2021127872A (ru) 2016-06-30 2021-11-09 Онкорус, Инк. Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
JP6699423B2 (ja) 2016-07-21 2020-05-27 コニカミノルタ株式会社 定着装置および画像形成装置
CN110139873A (zh) 2016-10-03 2019-08-16 朱诺治疗学股份有限公司 Hpv特异性结合分子
IL266628B2 (en) 2016-11-17 2024-06-01 Bluebird Bio Inc TGFBeta signal converter
US11497768B2 (en) 2017-06-05 2022-11-15 Mie University Antigen-binding protein that recognizes MAGE-A4-derived peptide
AU2018318303A1 (en) 2017-08-18 2020-04-09 Gritstone Bio, Inc. Antigen-binding proteins targeting shared antigens
EP3695408B1 (en) 2017-10-02 2026-01-21 The Broad Institute, Inc. Medical use of cdk4/6- and checkpoint-inhibitors in phased combination, in treatment of cancer
WO2019238023A1 (en) 2018-06-11 2019-12-19 Chineo Medical Technology Co., Ltd. Neoantigen vaccines and uses thereof
EP3714941A1 (en) 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
KR20220030933A (ko) 2019-05-08 2022-03-11 메디진 이뮤노테라피스 게엠바하 조작된 t 세포

Similar Documents

Publication Publication Date Title
JP2022532557A5 (https=)
CN305758407S (https=)
CN305756092S (https=)
CN305533461S (https=)
CN305532751S (https=)
CN305532289S (https=)
CN305530644S (https=)
CN305530041S (https=)
CN305529824S (https=)
CN305529414S (https=)
CN305528914S (https=)
CN305866890S (https=)
CN305865990S (https=)
CN305527691S (https=)
CN305865605S (https=)
CN305864907S (https=)
CN305862346S (https=)
CN305860328S (https=)
CN305757284S (https=)
CN305857106S (https=)
CN305852447S (https=)
CN305850652S (https=)
CN305849677S (https=)
CN305831560S (https=)
CN305830352S (https=)